Clinical implication of CD166 expression in gastric cancer

Journal of Surgical Oncology

Volumn 103, Issue 1, 2011, Pages 57-61

  Ishigami, Sumiya ^a   Ueno, Shinichi ^a   Arigami, Takaaki ^a   Arima, Hideo ^a   Uchikado, Yasuto ^a   Kita, Yoshiaki ^a   Sasaki, Ken ^a   Nishizono, Yuka ^a   Omoto, Itaru ^a   Kurahara, Hiroshi ^a   Matsumoto, Masataka ^a   Kijima, Yuko ^a   Natsugoe, Shoji ^a  

^a KAGOSHIMA UNIVERSITY   (Japan)

Author keywords

CD166; cytoplasm; gastric cancer; lymph node metastasis; membrane; prognosis

Indexed keywords

ACTIVATED LEUKOCYTE CELL ADHESION MOLECULE; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER INVASION; CANCER PATIENT; CANCER SURVIVAL; CELL MEMBRANE; CYTOPLASM; FEMALE; GASTRECTOMY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LEUKOCYTE MOTILITY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; STOMACH CANCER; TREATMENT OUTCOME;

ACTIVATED-LEUKOCYTE CELL ADHESION MOLECULE; ADULT; AGED; AGED, 80 AND OVER; CELL MEMBRANE; CYTOPLASM; FEMALE; FOLLOW-UP STUDIES; GASTRECTOMY; HUMANS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; PROGNOSIS; STOMACH NEOPLASMS; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 78650635846     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.21756     Document Type: Article

References (25)

1. Desgrosellier JS, Cheresh DA,: Integrins in cancer: Biological implications and therapeutic opportunities. Nat Rev Cancer 2010; 10: 9-22.
2. Makrilia N, Kollias A, Manolopoulos L, et al.: Cell adhesion molecules: Role and clinical significance in cancer. Cancer Invest 2009; 27: 1023-1037.
3. Cook G, Dumbar M, Franklin IM,: The role of adhesion molecules in multiple myeloma. Acta Haematol 1997; 97: 81-89.
4. Kobayashi H, Boelte KC, Lin PC,: Endothelial cell adhesion molecules and cancer progression. Curr Med Chem 2007; 14: 377-386.
5. Swart GW,: Activated leukocyte cell adhesion molecule (CD166/ALCAM): Developmental and mechanistic aspects of cell clustering and cell migration. Eur J Cell Biol 2002; 81: 313-321.
6. van Kempen LC, Nelissen JM, Degen WG, et al.: Molecular basis for the homophilic activated leukocyte cell adhesion molecule (ALCAM)-ALCAM interaction. Biol Chem 2001; 276: 25783-25790.
7. Cayrol R, Wosik K, Berard JL, et al.: Activated leukocyte cell adhesion molecule promotes leukocyte trafficking into the central nervous system. Nat Immunol 2008; 9: 137-145.
8. Masedunskas A, King JA, Tan F, et al.: Activated leukocyte cell adhesion molecule is a component of the endothelial junction involved in transendothelial monocyte migration. FEBS Lett 2006; 580: 2637-2645.
9. Bowen MA, Aruffo A,: Adhesion molecules, their receptors, and their regulation: Analysis of CD6-activated leukocyte cell adhesion molecule (ALCAM/CD166) interactions. Transplant Proc 1999; 31: 795-796.
10. Campbell IG, Foulkes WD, Senger G, et al.: Molecular cloning of the B-CAM cell surface glycoprotein of epithelial cancers: A novel member of the immunoglobulin superfamily. Cancer Res 1994; 54: 5761-5765.
11. King JA, Chambers Z, Kleinfeld S, et al.: Potential role of activated leukocyte cell adhesion molecule (ALCAM/CD166) in metastasis of breast cancer cells to the lung. Proc Am Assoc Cancer Res 2006; 47: 2784.
12. Kristiansen G, Pilarsky C, Wissmann C, et al.: ALCAM/CD166 is up-regulated in low-grade prostate cancer and progressively lost in high-grade lesions. Prostate 2003; 54: 34-43.
13. Mezzanzanica D, Fabbi M, Bagnoli M, et al.: Subcellular localization of activated leukocyte cell adhesion molecule is a molecular predictor of survival in ovarian carcinoma patients. Clin Cancer Res 2008; 14: 1726-1733.
14. Kahlert C, Weber H, Mogler C, et al.: Increased expression of ALCAM/CD166 in pancreatic cancer is an independent prognostic marker for poor survival and early tumour relapse. Br J Cancer 2009; 101: 457-464.
15. Sawhney M, Matta A, Macha MA, et al.: Cytoplasmic accumulation of activated leukocyte cell adhesion molecule is a predictor of disease progression and reduced survival in oral cancer patients. Int J Cancer 2009; 124: 2098-2105.
16. van Kempen LC, van den Oord JJ, van Muijen GN, et al.: Activated leukocyte cell adhesion molecule/CD166, a marker of tumor progression in primary malignant melanoma of the skin. Am J Pathol 2000; 156: 769-774.
17. Weichert W, Knosel T, Bellach J, et al.: ALCAM/CD166 is overexpressed in colorectal carcinoma and correlates with shortened patient survival. J Clin Pathol 2004; 57: 1160-1164.
18. Japanese Gastric Cancer Association: Japanese Classification of Gastric Carcinoma, 2nd English edition. Gastric Cancer 1998; 1: 10-24.
19. Rosso O, Piazza T, Bongarzone I, et al.: The ALCAM shedding by the metalloprotease ADAM17/TACE is involved in motility of ovarian carcinoma cells. Mol Cancer Res 2007; 5: 1246-1253.
20. van Kilsdonk JW, Wilting RH, Bergers M, et al.: Attenuation of melanoma invasion by a secreted variant of activated leukocyte cell adhesion molecule. Cancer Res 2008; 68: 3671-3679.
21. Jezierska A, Matysiak W, Motyl T,: ALCAM/CD166 protects breast cancer cells against apoptosis and autophagy. Med Sci Monit 2006; 12: BR263-BR273. (Pubitemid 44186369)
22. Ofori-Acquah SF, King JA,: Activated leukocyte cell adhesion molecule: A new paradox in cancer. Transl Res 2008; 151: 122-128.
23. Burkhardt M, Mayordomo E, Winzer KJ, et al.: Cytoplasmic overexpression of ALCAM is prognostic of disease progression in breast cancer. J Clin Pathol 2006; 59: 403-409.
24. Ihnen M, Müller V, Wirtz RM, et al.: Predictive impact of activated leukocyte cell adhesion molecule (ALCAM/CD166) in breast cancer. Breast Cancer Res Treat 2008; 112: 419-427.
25. King J, Ofori-Acquah S, Stevens T, et al.: Potential role for activated leukocyte cell adhesion molecule and neural cadherin in metastasis to the lung microcirculation. Chest 2004; 125: 150S-151S.